CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 50 enrolled
Drug / intervention
Seroguard +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03640559
NCT03640559Phase 1Completed
CompareCT.gov

Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study of Safety and Tolerability of Seroguard, Solution (JSC Pharmasyntez, Russia) in Patients Undergoing a Planned Laparoscopic Cholecystectomy

Pharmasyntez·interventional·Posted Aug 21, 2018·Updated May 3, 2019

In Brief

A Phase 1 clinical trial evaluating Seroguard and Placebos for Adhesion. Completed, enrolled 50 participants.

Detailed Summary

The performed study of safety and tolerability of Seroguard, solution (JSC Pharmasyntez, Russia) in patients, undergoing planned laparoscopic cholecystectomy, demonstrated that patients from the both groups had the similar safety profile

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdhesion
Countries--
CollaboratorsSciencefiles

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 21, 2018
Enrollment StartMay 19, 2015
Primary CompletionOct 4, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.9 years ago

Interventions

Seroguarddrug

Placebosdrug